New injection after liver ablation aims to stop colorectal cancer in its tracks
NCT ID NCT07321847
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new drug called IP-001, injected into the liver after standard heat-based tumor destruction, can help prevent colorectal cancer from coming back. About 717 adults with colorectal cancer that has spread only to the liver will be randomly assigned to receive either standard ablation alone or ablation plus a low or high dose of IP-001. The goal is to see if the injection activates the immune system to find and destroy any remaining cancer cells, reducing the risk of recurrence and spread.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact